William Blair Weighs in on Exagen’s Q1 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN) – Equities researchers at William Blair upped their Q1 2025 EPS estimates for shares of Exagen in a research note issued on Wednesday, March 12th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($0.20) per share for the quarter, up from their previous forecast of ($0.24). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

XGN has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th. Canaccord Genuity Group increased their price objective on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

Exagen Trading Up 6.3 %

NASDAQ XGN opened at $3.56 on Friday. The stock has a market capitalization of $62.79 million, a PE ratio of -3.79 and a beta of 1.40. Exagen has a 52 week low of $1.30 and a 52 week high of $6.22. The firm has a 50 day moving average of $3.78 and a two-hundred day moving average of $3.58. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Institutional Investors Weigh In On Exagen

Several hedge funds have recently modified their holdings of the company. Toronto Dominion Bank acquired a new stake in shares of Exagen during the 4th quarter worth about $3,655,000. Driehaus Capital Management LLC acquired a new stake in shares of Exagen during the 4th quarter worth about $1,716,000. Northern Trust Corp boosted its stake in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Exagen during the 4th quarter worth about $66,000. Finally, Kennedy Capital Management LLC boosted its stake in shares of Exagen by 8.8% during the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock worth $756,000 after purchasing an additional 14,920 shares during the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).